By Research and Markets (http://www.researchandmarkets.com/research/gg9n3c/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering.
'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer.
Scope
- A snapshot of the global therapeutic scenario for Thyroid Cancer.
- A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Bio-Path Holdings, Inc.
- Eisai Co., Ltd.
- Bayer AG
- Bionomics Limited
- Azaya Therapeutics Incorporated
- Vascular Biogenics Ltd.
- Biovista Inc.
- Trophogen, Inc.
- centrose llc
- Ecrins Therapeutics SAS
For more information visit http://www.researchandmarkets.com/research/gg9n3c/thyroid_cancer
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology
